Cupric Chloride Anhydrous

We are Cupric Chloride Anhydrous CAS:7447-39-4 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Other name: 
Cupric Chloride Anhydrous

 

CAS No.: 7447-39-4

Molecular Weight: 134.45
 

Characters: It is brownish yellow crystal, easily soluble in water, can easily absorb moisture. aqueous solution is weakly acidic, b.p.: 993℃, m.p.: 620℃

Specifications:

Cupric chloride anhydrous	Export High-purity	A.R.	Technical grade
Item	Spec.	Spec.	Spec.
Assay(as CuCl2)%	≥99.9	≥99.0	≥98.0
Copper content (asCu)%	≥47.0	≥46.5	≥46.0
Water insoluble%	≤0.003	≤0.005	≤0.1
Sulphates(SO4-)%	≤0.003	≤0.003	≤0.03
Fe%	≤0.02	≤0.02	≤0.02
Zn%	≤0.02	≤0.02	≤0.02
Fineness(80-mesh sieve residue) %	—	—	—

Product Usage: Catalyst and dye mordant. glass, colorant for ceramic, as catalyst and mordant in oxidation reaction.

Packaging: 25kg woven bag, lined with double-layer plastic bag

Storage Precautions: Stored in cool, dry and draughty warehouse, sealed tightly handle with care

Related News: Government officials say that the number of visitors from the mainland and other countries has decreased significantly after they closed several border points and rail stations and cut flight arrivals by half.5-Bromo-4-methylpyridine-2-carboxylic acid An analysis of the top 20 global companies by R&D spend for 2018 shows that companies with expensive late-stage pipeline drugs are spending significant proportions of their annual revenue on R&D.2,4,6-Trimethyliodobenzene CAS:4028-63-1 An analysis of the top 20 global companies by R&D spend for 2018 shows that companies with expensive late-stage pipeline drugs are spending significant proportions of their annual revenue on R&D.6233-83-6 ViiV, in which Pfizer and Shionogi have small stakes, said it received a so-called complete response letter (CRL) from the FDA in which the regulator questioned the treatment’s chemistry, manufacturing and controls process, but not its safety.DMF is the main management method for APIs in developed countries in Europe and the United States. Under the DMF system, API companies can submit DMF filing documents to the regulatory authority at any time, but the regulatory authority will not conduct technical reviews on them. When the drug is administered, the regulatory authority will associate and review the drug substance and the preparation.